Tranexamic acid: optimal blood loss management in surface replacement arthroplasty.
2016
Aims This study investigated whether the use of tranexamic acid (TXA)
decreased blood loss and transfusion related cost following surface
replacement arthroplasty (SRA). Methods A retrospective review of patients treated with TXA during a
SRA, who did not receive autologous blood (TXA group) was performed.
Two comparison groups were established; the first group comprised
of patients who donated their own blood pre-operatively (auto group)
and the second of patients who did not donate blood pre-operatively
(control). Outcomes included transfusions, post-operative haemoglobin
(Hgb), complications, and length of post-operative stay. Results Between 2009 and 2013, 150 patients undergoing SRA were identified
for inclusion: 51 in the auto, 49 in the control, and 50 in the
TXA group. There were no differences in the pre-operative Hgb concentrations
between groups. The mean post-operative Hgb was 11.3 g/dL (9.1 to
13.6) in the auto and TXA groups, and 10.6 g/dL (8.1 to 12.1)in
the control group (p = 0.001). Accounting for cost of transfusions,
administration of TXA, and length of stay, the cost per patient
was $1731, $339, and $185 for the auto, control and TXA groups,
respectively. Discussion TXA use demonstrated higher post-operative Hgb concentrations
when compared with controls and decreased peri-operative costs. Take home message: Tranexamic acid safely limits allogeneic transfusion,
maintains post-operative haemoglobin, and decreases direct and indirect
transfusion related costs in surface replacement arthroplasty. Cite this article: Bone Joint J 2016;98-B:173–8.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
22
References
12
Citations
NaN
KQI